gip glp-1 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Comparison between GLP-1 RA and
Description
Kenneth W Mahaffey, Department of Medicine, Stanford Center for Clinical Research, Stanford School of Medicine, Palo Alto, CA, USA
From the perspective of scientific research, existing recommendations for analytic procedures in real-world-study-based CEAs remain insufficient [7, 8, 51]
& Schmid, H
Semaglutide Lowers Body Weight in Rodents via Distributed Neural Pathways
10.1016/j.molmet.2024.101880 73 Outeirino-IglesiasV.Romani-PerezM.Gonzalez-MatiasL
